<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>PHENYTOIN - phenytoin suspension </strong><br>Physicians Total Care, Inc.<br></p></div>
<h1>PHENYTOIN ORAL SUSPENSION, USP <br>(Not for Parenteral Use)</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="DLDE"></a><a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-1"></a><p></p>
<h1></h1>
<p class="First"><span class="Bold">125 mg/5 mL</span></p>
<p><span class="Bold">Rx only</span></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="section-2"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">Phenytoin is related to the barbiturates in chemical structure, but has a five-membered ring. The chemical name is 5,5-Diphenylhydantoin, having the following structural formula:</p>
<div class="Figure"><img alt="Chemical Structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=9ce9adc8-6fa2-4444-8386-14cd576ac63d&amp;name=phenytoin-image01.jpg"></div>
<p>Each 5 mL (teaspoonful) of suspension contains 125 mg of phenytoin, USP with an alcohol content of 0.35 percent. Also contains carboxymethylcellulose sodium, citric acid anhydrous, dehydrated alcohol, FD&amp;C Yellow No. 6, glycerin, liquid sugar, magnesium aluminum silicate, orange flavor, polysorbate 40, purified water, sodium benzoate, sodium citrate dihydrate and vanillin. It may contain 10% citric acid solution or 10% sodium citrate solution to adjust pH. The pH range is between 3.6 and 5.2.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="clinical"></a><a name="section-3"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<p class="First">Phenytoin is an antiepileptic drug which can be useful in the treatment of <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span>. The primary site of action appears to be <span class="Italics">the motor cortex</span> where spread of <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> activity is inhibited. Possibly by promoting sodium efflux from neurons, phenytoin tends to <span class="Italics">stabilize</span> the threshold against <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">hyperexcitability</span> caused by excessive stimulation or environmental changes capable of reducing membrane sodium gradient. This includes the reduction of posttetanic potentiation at synapses. Loss of posttetanic potentiation prevents cortical <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> foci from detonating adjacent cortical areas. Phenytoin reduces the maximal activity of brain stem centers responsible for the tonic phase of tonic-clonic (<span class="product-label-link" type="condition" conceptid="374924" conceptname="Generalized convulsive epilepsy">grand mal</span>) <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>.</p>
<p>The plasma half-life in man after oral administration of phenytoin averages 22 hours, with a range of 7 to 42 hours. Steady-state therapeutic levels are achieved at least 7 to 10 days (5–7 half-lives) after initiation of therapy with recommended doses of 300 mg/day.</p>
<p>When serum level determinations are necessary, they should be obtained at least 5–7 half-lives after treatment initiation, dosage change, or addition or subtraction of another drug to the regimen so that equilibrium or steady-state will have been achieved. Trough levels provide information about clinically effective serum level range and confirm patient compliance and are obtained just prior to the patient's next scheduled dose. Peak levels indicate an individual's threshold for emergence of dose-related side effects and are obtained at the time of expected peak concentration. For Phenytoin Oral Suspension peak levels occur 1½–3 hours after administration.</p>
<p>Optimum control without clinical signs of toxicity occurs more often with serum levels between 10 and 20 mcg/mL, although some mild cases of tonic-clonic (<span class="product-label-link" type="condition" conceptid="374924" conceptname="Generalized convulsive epilepsy">grand mal</span>) <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span> may be controlled with lower serum levels of phenytoin.</p>
<p>In most patients maintained at a steady dosage, stable phenytoin serum levels are achieved. There may be wide interpatient variability in phenytoin serum levels with equivalent dosages. Patients with unusually low levels may be noncompliant or hypermetabolizers of phenytoin. Unusually high levels result from liver disease, congenital enzyme deficiency, or drug interactions which result in metabolic interference. The patient with large variations in phenytoin plasma levels, despite standard doses, presents a difficult clinical problem. Serum level determinations in such patients may be particularly helpful. As phenytoin is highly protein bound, free phenytoin levels may be altered in patients whose protein binding characteristics differ from normal.</p>
<p>Most of the drug is excreted in the bile as inactive metabolites which are then reabsorbed from the intestinal tract and excreted in the urine. Urinary excretion of phenytoin and its metabolites occurs partly with glomerular filtration but more importantly, by tubular secretion. Because phenytoin is hydroxylated in the liver by an enzyme system which is saturable at high plasma levels small incremental doses may increase the half-life and produce very substantial increases in serum levels, when these are in the upper range. The steady-state level may be disproportionately increased, with resultant <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">intoxication</span>, from an increase in dosage of 10% or more.</p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="section-4"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<p class="First">Phenytoin Oral Suspension is indicated for the control of tonic-clonic (<span class="product-label-link" type="condition" conceptid="374924" conceptname="Generalized convulsive epilepsy">grand mal</span>) and psychomotor (temporal lobe) <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>.</p>
<p>Phenytoin serum level determinations may be necessary for optimal dosage adjustments (see <span class="Bold"><a href="#dosage">DOSAGE AND ADMINISTRATION</a></span> and <span class="Bold"><a href="#clinical">CLINICAL PHARMACOLOGY</a></span> sections).</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="contraindications"></a><a name="section-5"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First">Phenytoin Oral Suspension is contraindicated in those patients with a history of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to phenytoin or other hydantoins.</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="warnings"></a><a name="section-6"></a><p></p>
<h1>WARNINGS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.1"></a><p></p>
<h2>Effects of Abrupt Withdrawal</h2>
<p class="First">Abrupt withdrawal of phenytoin in epileptic patients may precipitate <span class="product-label-link" type="condition" conceptid="373748" conceptname="Grand mal status">status epilepticus</span>. When in the judgment of the clinician the need for dosage reduction, discontinuation, or substitution of alternative anticonvulsant medication arises, this should be done gradually. In the event of an allergic or <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reaction</span>, more rapid substitution of alternative therapy may be necessary. In this case, alternative therapy should be an anticonvulsant not belonging to the hydantoin chemical class.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.2"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="4322252" conceptname="Suicidal behavior">Suicidal Behavior</span> and Ideation</h2>
<p class="First">Antiepileptic drugs (AEDs), including phenytoin, increase the risk of suicidal thoughts or behavior in patients taking these drugs for any indication. Patients treated with any AED for any indication should be monitored for the emergence or worsening of <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, suicidal thoughts or behavior, and/or any unusual changes in mood or behavior.</p>
<p>Pooled analyses of 199 placebo-controlled clinical trials (mono- and adjunctive therapy) of 11 different AEDs showed that patients randomized to one of the AEDs had approximately twice the risk (adjusted Relative Risk 1.8, 95% CI:1.2, 2.7) of suicidal thinking or behavior compared to patients randomized to placebo. In these trials, which had a median treatment duration of 12 weeks, the estimated incidence rate of <span class="product-label-link" type="condition" conceptid="4322252" conceptname="Suicidal behavior">suicidal behavior</span> or ideation among 27,863 AED-treated patients was 0.43%, compared to 0.24% among 16,029 placebo-treated patients, representing an increase of approximately one case of suicidal thinking or behavior for every 530 patients treated. There were four <span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">suicides</span> in drug-treated patients in the trials and none in placebo-treated patients, but the number is too small to allow any conclusion about drug effect on <span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">suicide</span>.</p>
<p>The increased risk of suicidal thoughts or behavior with AEDs was observed as early as one week after starting drug treatment with AEDs and persisted for the duration of treatment assessed. Because most trials included in the analysis did not extend beyond 24 weeks, the risk of suicidal thoughts or behavior beyond 24 weeks could not be assessed.</p>
<p>The risk of suicidal thoughts or behavior was generally consistent among drugs in the data analyzed. The finding of increased risk with AEDs of varying mechanisms of action and across a range of indications suggests that the risk applies to all AEDs used for any indication. The risk did not vary substantially by age (5-100 years) in the clinical trials analyzed.</p>
<p>Table 1 shows absolute and relative risk by indication for all evaluated AEDs.</p>
<a name="table1"></a><table width="100%">
<caption><span>Table 1: Risk by indication for antiepileptic drugs in the pooled analysis</span></caption>
<col align="left" valign="top" width="20%">
<col align="left" valign="top" width="20%">
<col align="left" valign="top" width="20%">
<col align="left" valign="top" width="20%">
<col align="left" valign="top" width="20%">
<thead><tr class="First Last">
<th align="left">Indication</th>
<th align="left">Placebo Patients with Events Per 1000 Patients</th>
<th align="left">Drug Patients with Events Per 1000 Patients</th>
<th align="left">Relative Risk: Incidence of Events in Drug Patients/Incidence in Placebo Patients</th>
<th align="left">Risk Difference: Additional Drug Patients with Events Per 1000 Patients</th>
</tr></thead>
<tbody>
<tr class="First">
<td align="left"><span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">Epilepsy</span></td>
<td align="left">1.0</td>
<td align="left">3.4</td>
<td align="left">3.5</td>
<td align="left">2.4</td>
</tr>
<tr>
<td align="left">Psychiatric</td>
<td align="left">5.7</td>
<td align="left">8.5</td>
<td align="left">1.5</td>
<td align="left">2.9</td>
</tr>
<tr>
<td align="left">Other</td>
<td align="left">1.0</td>
<td align="left">1.8</td>
<td align="left">1.9</td>
<td align="left">0.9</td>
</tr>
<tr class="Last">
<td align="left">Total</td>
<td align="left">2.4</td>
<td align="left">4.3</td>
<td align="left">1.8</td>
<td align="left">1.9</td>
</tr>
</tbody>
</table>
<p>The relative risk for suicidal thoughts or behavior was higher in clinical trials for <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span> than in clinical trials for psychiatric or other conditions, but the absolute risk differences were similar for the <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span> and psychiatric indications.</p>
<p>Anyone considering prescribing phenytoin or any other AED must balance the risk of suicidal thoughts or behavior with the risk of untreated illness. <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">Epilepsy</span> and many other illnesses for which AEDs are prescribed are themselves associated with morbidity and mortality and an increased risk of suicidal thoughts and behavior. Should suicidal thoughts and behavior emerge during treatment, the prescriber needs to consider whether the emergence of these symptoms in any given patient may be related to the illness being treated.</p>
<p>Patients, their caregivers, and families should be informed that AEDs increase the risk of suicidal thoughts and behavior and should be advised of the need to be alert for the emergence or worsening of the signs and symptoms of <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, any unusual changes in mood or behavior, or the emergence of suicidal thoughts, behavior, or thoughts about self-harm. Behaviors of concern should be reported immediately to healthcare providers.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.3"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="315085" conceptname="Lymphadenopathy">Lymphadenopathy</span></h2>
<p class="First">There have been a number of reports suggesting a relationship between phenytoin and the development of <span class="product-label-link" type="condition" conceptid="315085" conceptname="Lymphadenopathy">lymphadenopathy</span> (local or generalized) including benign lymph node <span class="product-label-link" type="condition" conceptid="4296894" conceptname="Hyperplasia">hyperplasia</span>, <span class="product-label-link" type="condition" conceptid="4027114" conceptname="Pseudolymphoma">pseudolymphoma</span>, <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span>, and Hodgkin's disease. Although a cause and effect relationship has not been established, the occurrence of <span class="product-label-link" type="condition" conceptid="315085" conceptname="Lymphadenopathy">lymphadenopathy</span> indicates the need to differentiate such a condition from other types of lymph node pathology. Lymph node involvement may occur with or without symptoms and signs resembling <span class="product-label-link" type="condition" conceptid="432522" conceptname="Transfusion reaction due to serum protein reaction">serum sickness</span> e.g., <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, and liver involvement.</p>
<p>In all cases of <span class="product-label-link" type="condition" conceptid="315085" conceptname="Lymphadenopathy">lymphadenopathy</span>, follow-up observation for an extended period is indicated and every effort should be made to achieve <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> control using alternative antiepileptic drugs.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.4"></a><p></p>
<h2>Effects of Alcohol Use on Phenytoin Serum Levels</h2>
<p class="First">Accute alcoholic intake may increase phenytoin serum levels, while chronic alcoholic use may decrease serum levels.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.5"></a><p></p>
<h2>Exacerbation of <span class="product-label-link" type="condition" conceptid="4305376" conceptname="Porphyria">Porphyria</span></h2>
<p class="First">In view of isolated reports associating phenytoin with exacerbation of <span class="product-label-link" type="condition" conceptid="4305376" conceptname="Porphyria">porphyria</span>, caution should be exercised in using this medication in patients suffering from this disease.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.6"></a><p></p>
<h2>Usage in Pregnancy</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.6.1"></a><p></p>
<h3></h3>
<p class="First"><span class="Italics">Clinical:</span></p>
<ol class="BigAlpha">
<li>
<span class="Italics">Risks to Mother.</span> An increase in <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> frequency may occur during pregnancy because of altered phenytoin pharmacokinetics. Periodic measurement of plasma phenytoin concentrations may be valuable in the management of pregnant women as a guide to appropriate adjustment of dosage (see <span class="Bold"><a href="#precautions_labtests">PRECAUTIONS, Laboratory Tests</a></span>). However, postpartum restoration of the original dosage will probably be indicated.</li>
<li>
<span class="Italics">Risks to the Fetus.</span> If this drug is used during pregnancy, or if the patient becomes pregnant while taking the drug, the patient should be apprised of the potential harm to the fetus.<br>Prenatal exposure to phenytoin may increase the risks for congenital malformations and other adverse developmental outcomes. Increased frequencies of major malformations (such as orofacial clefts and cardiac defects), minor anomalies (dysmorphic facial features, nail and digit hypoplasia), growth abnormalities (including <span class="product-label-link" type="condition" conceptid="381114" conceptname="Microcephalus">microcephaly</span>), and <span class="product-label-link" type="condition" conceptid="440389" conceptname="Mental retardation">mental deficiency</span> have been reported among children born to epileptic women who took phenytoin alone or in combination with other antiepileptic drugs during pregnancy. There have also been several reported cases of malignancies, including <span class="product-label-link" type="condition" conceptid="4333766" conceptname="Neuroblastoma">neuroblastoma</span>, in children whose mothers received phenytoin during pregnancy. The overall incidence of malformations for children of epileptic women treated with antiepileptic drugs (phenytoin and/or others) during pregnancy is about 10%, or two- to three-fold that in the general population. However, the relative contributions of antiepileptic drugs and other factors associated with <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span> to this increased risk are uncertain and in most cases it has not been possible to attribute specific developmental abnormalities to particular antiepileptic drugs.<br>										Patients should consult with their physicians to weigh the risks and benefits of phenytoin during pregnancy.</li>
<li>
<span class="Italics">Postpartum Period.</span> A potentially life-threatening <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> disorder related to decreased levels of vitamin K-dependent clotting factors may occur in newborns exposed to phenytoin <span class="Italics">in utero.</span> This drug-induced condition can be prevented with vitamin K administration to the mother before delivery and to the neonate after birth.</li>
</ol>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.6.2"></a><p></p>
<h3>Preclinical</h3>
<p class="First">Increased resorption and malformation rates have been reported following administration of phenytoin doses of 75 mg/kg or higher (approximately 120% of the maximum human loading dose or higher on a mg/m<span class="Sup">2</span> basis) to pregnant rabbits.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="precautions"></a><a name="section-7"></a><p></p>
<h1>PRECAUTIONS</h1>
<div class="Section" data-sectionCode="34072-9">
<a name="section-7.1"></a><p></p>
<h2>General</h2>
<p class="First">The liver is the chief site of biotransformation of phenytoin; patients with <span class="product-label-link" type="condition" conceptid="4326594" conceptname="Abnormal liver function">impaired liver function</span>, elderly patients, or those who are gravely ill may show early signs of toxicity.</p>
<p>A small percentage of individuals who have been treated with phenytoin have been shown to metabolize the drug slowly. Slow metabolism may be due to limited enzyme availability and lack of induction; it appears to be genetically determined.</p>
<p>Phenytoin should be discontinued if a <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">skin rash</span> appears (see <span class="Bold"><a href="#warnings">WARNINGS</a></span> section regarding drug discontinuation). If the <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> is exfoliative, purpuric, or bullous or if <span class="product-label-link" type="condition" conceptid="255891" conceptname="Lupus erythematosus">lupus erythematosus</span>, <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson syndrome</span>, or <span class="product-label-link" type="condition" conceptid="443754" conceptname="Lyell's toxic epidermal necrolysis, subepidermal type">toxic epidermal necrolysis</span> is suspected, use of this drug should not be resumed and alternative therapy should be considered (see <span class="Bold"><a href="#adverse">ADVERSE REACTIONS</a></span> section). If the <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> is of a milder type (<span class="product-label-link" type="condition" conceptid="4030555" conceptname="Measles">measles</span>-like or scarlatiniform), therapy may be resumed after the <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> has completely disappeared. If the <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> recurs upon reinstitution of therapy, further phenytoin medication is contraindicated.</p>
<p>Phenytoin and other hydantoins are contraindicated in patients who have experienced phenytoin <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> (see <span class="Bold"><a href="#contraindications">CONTRAINDICATIONS</a></span>). Additionally, caution should be exercised if using structurally similar (e.g., barbiturates, succinamides, oxazolidinediones and other related compounds) in these same patients. <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">Hyperglycemia</span>, resulting from the drug's inhibitory effects on insulin release, has been reported. Phenytoin may also raise the serum glucose level in diabetic patients.</p>
<p><span class="product-label-link" type="condition" conceptid="432594" conceptname="Osteomalacia">Osteomalacia</span> has been associated with phenytoin therapy and is considered to be due to phenytoin's interference with Vitamin D metabolism.</p>
<p>Phenytoin is not indicated for <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> due to hypoglycemic or other metabolic causes. Appropriate diagnostic procedures should be performed as indicated.</p>
<p>Phenytoin is not effective for absence (<span class="product-label-link" type="condition" conceptid="4194232" conceptname="Absence seizure">petit mal</span>) <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>. If tonic-clonic (<span class="product-label-link" type="condition" conceptid="374924" conceptname="Generalized convulsive epilepsy">grand mal</span>) and absence (<span class="product-label-link" type="condition" conceptid="4194232" conceptname="Absence seizure">petit mal</span>) <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> are present, combined drug therapy is needed.</p>
<p>Serum levels of phenytoin sustained above the optimal range may produce <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusional states</span> referred to as "<span class="product-label-link" type="condition" conceptid="373995" conceptname="Delirium">delirium</span>,""<span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychosis</span>," or "<span class="product-label-link" type="condition" conceptid="372887" conceptname="Disorder of brain">encephalopathy</span>," or rarely irreversible cerebellar dysfunction. Accordingly, at the first sign of acute toxicity, plasma levels are recommended. Dose reduction of phenytoin therapy is indicated if plasma levels are excessive; if symptoms persist, termination is recommended (see <span class="Bold"><a href="#warnings">WARNINGS</a></span> section).</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="section-7.2"></a><p></p>
<h2>Information for Patients</h2>
<p class="First">Patients taking phenytoin should be advised of the importance of adhering strictly to the prescribed dosage regimen, and of informing the physician of any clinical condition in which it is not possible to take the drug orally as prescribed, e.g., surgery, etc.</p>
<p>Patients should be instructed to use an accurately calibrated measuring device when using this medication to ensure accurate dosing.</p>
<p>Patients should also be cautioned on the use of other drugs or alcoholic beverages without first seeking the physician's advice.</p>
<p>Patients should be instructed to call their physician if <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">skin rash</span> develops.</p>
<p>The importance of good dental hygiene should be stressed in order to minimize the development of gingival <span class="product-label-link" type="condition" conceptid="4296894" conceptname="Hyperplasia">hyperplasia</span> and its complications.</p>
<p>Patients, their caregivers, and families should be counseled that AEDs, including phenytoin, may increase the risk of suicidal thoughts and behavior and should be advised of the need to be alert for the emergence or worsening of symptoms of <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, any unusual changes in mood or behavior, or the emergence of suicidal thoughts, behavior, or thoughts about self-harm. Behaviors of concern should be reported immediately to healthcare providers.</p>
<p>Patients should be encouraged to enroll in the North American Antiepileptic Drug (NAAED) Pregnancy Registry if they become pregnant. This registry is collecting information about the safety of antiepileptic drugs during pregnancy. To enroll, patients can call the toll free number 1-888-233-2334 (see <span class="Bold"><a href="#PrePreg">PRECAUTIONS: Pregnancy</a></span> section).</p>
</div>
<div class="Section" data-sectionCode="34075-2">
<a name="precautions_labtests"></a><a name="section-7.3"></a><p></p>
<h2>Laboratory Tests</h2>
<p class="First">Phenytoin serum level determinations may be necessary to achieve optimal dosage adjustments.</p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="section-7.4"></a><p></p>
<h2>Drug Interactions</h2>
<p class="First">There are many drugs which may increase or decrease phenytoin levels or which phenytoin may affect. Serum level determinations for phenytoin are especially helpful when possible drug interactions are suspected. The most commonly occurring drug interactions are:</p>
<ol>
<li>Drugs which may increase phenytoin serum levels include: acute alcohol intake, amiodarone, chloramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H<span class="Sub">2</span>-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, ticlopidine, tolbutamide, trazodone.</li>
<li>Drugs which may decrease phenytoin levels include: carbamazepine, chronic <span class="product-label-link" type="condition" conceptid="433753" conceptname="Alcohol abuse">alcohol abuse</span>, reserpine, and sucralfate. <a name="footnote-reference-1" href="#footnote-1" class="Sup">1</a>Moban<span class="Sup">®</span> brand of molindone hydrochloride contains calcium ions which interfere with the absorption of phenytoin. Ingestion times of phenytoin and antacid preparations containing calcium should be staggered in patients with low serum phenytoin levels to prevent absorption problems.</li>
<li>Drugs which may either increase or decrease phenytoin serum levels include: phenobarbital, sodium valproate, and valproic acid. Similarly, the effect of phenytoin on phenobarbital, valproic acid, and sodium valproate serum levels is unpredictable.</li>
<li>Although not a true drug interaction, tricyclic antidepressants may precipitate <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> in susceptible patients and phenytoin dosage may need to be adjusted.</li>
<li>Drugs whose efficacy is impaired by phenytoin include: corticosteroids, coumarin anticoagulants, digitoxin, doxycycline, estrogens, furosemide, oral contraceptives, paroxetine, quinidine, rifampin, theophylline, vitamin D.</li>
</ol>
<hr class="Footnoterule">
<dl class="Footnote">
<dt><a name="footnote-1" href="#footnote-reference-1">1</a></dt>
<dd>(Moban<span class="Sup">®</span> is a registered trademark of Endo Pharmaceuticals, Inc.)</dd>
</dl>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.5"></a><p></p>
<h2>Drug Enteral Feeding/Nutritional Preparations Interaction</h2>
<p class="First">Literature reports suggest that patients who have received enteral feeding preparations and/or related nutritional supplements have lower than expected phenytoin plasma levels. It is therefore suggested that phenytoin not be administered concomitantly with an enteral feeding preparation. More frequent serum phenytoin level monitoring may be necessary in these patients.</p>
</div>
<div class="Section" data-sectionCode="34074-5">
<a name="section-7.6"></a><p></p>
<h2>Drug/Laboratory Test Interactions</h2>
<p class="First">Phenytoin may decrease serum concentrations of T4. It may also produce lower than normal values for dexamethasone or metyrapone tests. Phenytoin may cause increased serum levels of glucose, alkaline phosphatase, and gamma glutamyl transpeptidase (GGT).</p>
<p>Care should be taken when using immunoanalytical methods to measure plasma phenytoin concentrations.</p>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="section-7.7"></a><p></p>
<h2>Carcinogenesis</h2>
<p class="First">See <span class="Bold"><a href="#warnings">WARNINGS</a></span> section for information on carcinogenesis.</p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="PrePreg"></a><a name="section-7.8"></a><p></p>
<h2>Pregnancy</h2>
<div class="Section" data-sectionCode="34077-8">
<a name="section-7.8.1"></a><p></p>
<h3></h3>
<p class="First">Pregnancy Category D; See <span class="Bold"><a href="#warnings">WARNINGS</a></span> section.</p>
<p>To provide information regarding the effects of <span class="Italics">in utero</span> exposure to phenytoin, physicians are advised to recommend that pregnant patients taking phenytoin enroll in the NAAED Pregnancy Registry. This can be done by calling the toll free number 1-888-233-2334, and must be done by patients themselves. Information on the registry can also be found at the website http://www.aedpregnancyregistry.org/.</p>
</div>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="section-7.9"></a><p></p>
<h2>Nursing Mothers</h2>
<p class="First">Infant breast feeding is not recommended for women taking this drug because phenytoin appears to be secreted in low concentrations in human milk.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="section-7.10"></a><p></p>
<h2>Pediatric Use</h2>
<p class="First">See <span class="Bold"><a href="#dosage">DOSAGE AND ADMINISTRATION</a></span> section.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="adverse"></a><a name="section-8"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.1"></a><p></p>
<h2>Central Nervous System</h2>
<p class="First">The most common manifestations encountered with phenytoin therapy are referable to this system and are usually dose-related. These include <span class="product-label-link" type="condition" conceptid="378165" conceptname="Nystagmus">nystagmus</span>, <span class="product-label-link" type="condition" conceptid="437584" conceptname="Ataxia">ataxia</span>, <span class="product-label-link" type="condition" conceptid="4196636" conceptname="Dysarthria">slurred speech</span>, decreased coordination, and <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">mental confusion</span>. <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span>, <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, transient <span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">nervousness</span>, motor <span class="product-label-link" type="condition" conceptid="4247265" conceptname="Muscle twitch">twitchings</span>, and <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headaches</span> have also been observed. There have also been rare reports of phenytoin-induced <span class="product-label-link" type="condition" conceptid="4047115" conceptname="Oral dyskinesia">dyskinesias</span>, including <span class="product-label-link" type="condition" conceptid="440990" conceptname="Chorea">chorea</span>, <span class="product-label-link" type="condition" conceptid="375800" conceptname="Dystonia">dystonia</span>, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span> and <span class="product-label-link" type="condition" conceptid="4138992" conceptname="Asterixis">asterixis</span>, similar to those induced by phenothiazine and other neuroleptic drugs.</p>
<p>A predominantly sensory peripheral <span class="product-label-link" type="condition" conceptid="4174262" conceptname="Polyneuropathy">polyneuropathy</span> has been observed in patients receiving long-term phenytoin therapy.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.2"></a><p></p>
<h2>Gastrointestinal System</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>, toxic <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> and <span class="product-label-link" type="condition" conceptid="4352876" conceptname="Liver damage">liver damage</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.3"></a><p></p>
<h2>Integumentary System</h2>
<p class="First">Dermatological manifestations sometimes accompanied by <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> have included scarlatiniform or <span class="product-label-link" type="condition" conceptid="4083309" conceptname="Morbilliform eruption">morbilliform rashes</span>. A <span class="product-label-link" type="condition" conceptid="4083309" conceptname="Morbilliform eruption">morbilliform rash</span> (<span class="product-label-link" type="condition" conceptid="4030555" conceptname="Measles">measles</span>-like) is the most common; other types of <span class="product-label-link" type="condition" conceptid="133835" conceptname="Eczema">dermatitis</span> are seen more rarely. Other more serious forms which may be fatal have included bullous, exfoliative or purpuric <span class="product-label-link" type="condition" conceptid="133835" conceptname="Eczema">dermatitis</span>, <span class="product-label-link" type="condition" conceptid="255891" conceptname="Lupus erythematosus">lupus erythematosus</span>, <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson syndrome</span>, and <span class="product-label-link" type="condition" conceptid="443754" conceptname="Lyell's toxic epidermal necrolysis, subepidermal type">toxic epidermal necrolysis</span> (see <span class="Bold"><a href="#precautions">PRECAUTIONS</a></span> section).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.4"></a><p></p>
<h2>Hemopoietic System</h2>
<p class="First">Hemopoietic complications, some fatal, have occasionally been reported in association with administration of phenytoin. These have included <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>, <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>, <span class="product-label-link" type="condition" conceptid="4218497" conceptname="Granulocytopenic disorder">granulocytopenia</span>, <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">agranulocytosis</span>, and <span class="product-label-link" type="condition" conceptid="432881" conceptname="Pancytopenia">pancytopenia</span> with or without bone marrow suppression. While <span class="product-label-link" type="condition" conceptid="4248718" conceptname="Macrocytosis">macrocytosis</span> and <span class="product-label-link" type="condition" conceptid="435789" conceptname="Megaloblastic anemia">megaloblastic anemia</span> have occurred, these conditions usually respond to folic acid therapy. <span class="product-label-link" type="condition" conceptid="315085" conceptname="Lymphadenopathy">Lymphadenopathy</span> including benign lymph node <span class="product-label-link" type="condition" conceptid="4296894" conceptname="Hyperplasia">hyperplasia</span>, <span class="product-label-link" type="condition" conceptid="4027114" conceptname="Pseudolymphoma">pseudolymphoma</span>, <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span>, and Hodgkin's disease have been reported (see <span class="Bold"><a href="#warnings">WARNINGS</a></span> section).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.5"></a><p></p>
<h2>Connective Tissue System</h2>
<p class="First">Coarsening of the facial features, enlargement of the lips, gingival <span class="product-label-link" type="condition" conceptid="4296894" conceptname="Hyperplasia">hyperplasia</span>, <span class="product-label-link" type="condition" conceptid="443793" conceptname="Hypertrichosis">hypertrichosis</span>, and Peyronie's disease.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.6"></a><p></p>
<h2>Immunologic</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="45765791" conceptname="Drug reaction with eosinophilia and systemic symptoms">Hypersensitivity syndrome</span> (which may include, but is not limited to, symptoms such as <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">arthralgias</span>, <span class="product-label-link" type="condition" conceptid="4302954" conceptname="Disorder characterized by eosinophilia">eosinophilia</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, liver dysfunction, <span class="product-label-link" type="condition" conceptid="315085" conceptname="Lymphadenopathy">lymphadenopathy</span> or <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>), <span class="product-label-link" type="condition" conceptid="257628" conceptname="Systemic lupus erythematosus">systemic lupus erythematosus</span>, <span class="product-label-link" type="condition" conceptid="320749" conceptname="Polyarteritis nodosa">periarteritis nodosa</span> and immunoglobulin abnormalities.</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="section-9"></a><p></p>
<h1>OVERDOSAGE</h1>
<p class="First">The lethal dose in pediatric patients is not known. The lethal dose in adults is estimated to be 2 to 5 grams. The initial symptoms are <span class="product-label-link" type="condition" conceptid="378165" conceptname="Nystagmus">nystagmus</span>, <span class="product-label-link" type="condition" conceptid="437584" conceptname="Ataxia">ataxia</span>, and <span class="product-label-link" type="condition" conceptid="4196636" conceptname="Dysarthria">dysarthria</span>. Other signs are <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span>, <span class="product-label-link" type="condition" conceptid="4313132" conceptname="Hyperreflexia">hyperreflexia</span>, <span class="product-label-link" type="condition" conceptid="4061577" conceptname="Lethargy">lethargy</span>, <span class="product-label-link" type="condition" conceptid="4196636" conceptname="Dysarthria">slurred speech</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>. The patient may become <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">comatose</span> and hypotensive. <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">Death</span> is due to respiratory and circulatory <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>.</p>
<p>There are marked variations among individuals with respect to phenytoin plasma levels where toxicity may occur. <span class="product-label-link" type="condition" conceptid="378165" conceptname="Nystagmus">Nystagmus</span>, on lateral gaze, usually appears at 20 mcg/mL, <span class="product-label-link" type="condition" conceptid="437584" conceptname="Ataxia">ataxia</span> at 30 mcg/mL; <span class="product-label-link" type="condition" conceptid="4196636" conceptname="Dysarthria">dysarthria</span> and <span class="product-label-link" type="condition" conceptid="4061577" conceptname="Lethargy">lethargy</span> appear when the plasma concentration is over 40 mcg/mL, but as high a concentration as 50 mcg/mL has been reported without evidence of toxicity. As much as 25 times the therapeutic dose has been taken to result in a serum concentration over 100 mcg/mL with complete recovery.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-9.1"></a><p></p>
<h2>Treatment</h2>
<p class="First">Treatment is nonspecific since there is no known antidote.</p>
<p>The adequacy of the respiratory and circulatory systems should be carefully observed and appropriate supportive measures employed. Hemodialysis can be considered since phenytoin is not completely bound to plasma proteins. Total exchange transfusion has been used in the treatment of severe <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">intoxication</span> in pediatric patients.</p>
<p>In acute overdosage the possibility of other CNS depressants, including alcohol, should be borne in mind.</p>
</div>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="dosage"></a><a name="section-10"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION – (NOT FOR PARENTERAL USE)</h1>
<p class="First">Serum concentrations should be monitored and care should be taken when switching a patient from the sodium salt to the free acid form. The free acid form of phenytoin is used in Phenytoin Oral Suspension. Because there is approximately an 8% increase in drug content with the free acid form over that of the sodium salt, dosage adjustments and serum level monitoring may be necessary when switching from a product formulated with the free acid to a product formulated with the sodium salt and vice versa.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-10.1"></a><p></p>
<h2>General</h2>
<p class="First">Dosage should be individualized to provide maximum benefit. In some cases serum blood level determinations may be necessary for optimal dosage adjustments—the clinically effective serum level is usually 10–20 mcg/mL. With recommended dosage, a period of seven to ten days may be required to achieve steady-state blood levels with phenytoin and changes in dosage (increase or decrease) should not be carried out at intervals shorter than seven to ten days.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-10.2"></a><p></p>
<h2>Adult Dose</h2>
<p class="First">Patients who have received no previous treatment may be started on one teaspoonful (5 mL) of Phenytoin Oral Suspension three times daily, and the dose is then adjusted to suit individual requirements. An increase to five teaspoonfuls daily may be made, if necessary.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-10.3"></a><p></p>
<h2>Pediatric Dose</h2>
<p class="First">Initially, 5 mg/kg/day in two or three equally divided doses, with subsequent dosage individualized to a maximum of 300 mg daily. A recommended daily maintenance dosage is usually 4 to 8 mg/kg. Children over 6 years and adolescents may require the minimum adult dose (300 mg/day).</p>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="section-11"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First">Phenytoin Oral Suspension, USP 125 mg phenytoin/5 mL with an alcohol content of 0.35 percent, an orange suspension with an orange-vanilla flavor; available in 237 mL (8 fl oz) bottles  (<span class="Bold">NDC 54868-2038-0</span>).</p>
<div class="Section" data-sectionCode="44425-7">
<a name="section-11.1"></a><p></p>
<h2></h2>
<p class="First"><span class="Bold">Store at 20 °–25 °C (68 °–77 °F) [See USP Controlled Room Temperature]. Protect from freezing and light.</span></p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-12"></a><p></p>
<h1></h1>
<p class="First"><span class="Bold">Rx Only</span></p>
<p>Prod. No.: 8131</p>
<p><span class="Bold">Manufactured For:<br>Wockhardt USA, LLC<br>Parsippany, NJ 07054</span></p>
<p><span class="Bold">Manufactured By:<br>Morton Grove Pharmaceuticals, Inc.<br>Morton Grove, IL 60053</span></p>
<p>A50-8131-08<br>REV. 08-09</p>
<br><p><br></p>
<p>Relabeling of additional barcode by:<br>Physicians Total Care, Inc.<br>Tulsa, OK      74146<br></p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-13"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL - 237 mL Bottle</h1>
<p class="First"><span class="Bold">MGP</span></p>
<p><span class="Bold">NDC 54868-2038-0<br></span></p>
<p><span class="Bold">PHENYTOIN ORAL<br>SUSPENSION, USP<br>125 mg/5 mL</span></p>
<p><span class="Bold">(Not for Parenteral Use)</span></p>
<p><span class="Bold">Alcohol 0.35 percent</span></p>
<p><span class="Bold">IMPORTANT – SHAKE<br>WELL BEFORE EACH USE</span></p>
<p><span class="Bold">Rx Only</span></p>
<p><span class="Bold">NET: 237 mL (8 fl oz)</span></p>
<div class="Figure"><img alt="PRINCIPAL DISPLAY PANEL - 237 mL Bottle" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=9ce9adc8-6fa2-4444-8386-14cd576ac63d&amp;name=2038.jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>PHENYTOIN 		
					</strong><br><span class="contentTableReg">phenytoin suspension</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:54868-2038(NDC:60432-131)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>Phenytoin</strong> (Phenytoin) </td>
<td class="formItem">Phenytoin</td>
<td class="formItem">125 mg  in 5 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>magnesium aluminum silicate</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>glycerin</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>carboxymethylcellulose sodium</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>anhydrous citric acid</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>trisodium citrate dihydrate</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>sodium benzoate</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>raw sugar</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>polysorbate 40</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>water</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FD&amp;C Yellow No. 6</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>Alcohol</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>vanillin</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>Sodium Citrate</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>Citric Acid Monohydrate</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">    </td>
<td class="formLabel">Score</td>
<td class="formItem">    </td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem"></td>
<td class="formLabel">Size</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem">ORANGE (Orange-Vanilla) </td>
<td class="formLabel">Imprint Code</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:54868-2038-0</td>
<td class="formItem">237 mL in 1 BOTTLE, GLASS</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA040420</td>
<td class="formItem">12/19/2006</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Physicians Total Care, Inc.
							(194123980)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Physicians Total Care, Inc.</td>
<td class="formItem"></td>
<td class="formItem">194123980</td>
<td class="formItem">relabel, repack</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 8/2009<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>27378bdf-dca8-42b0-8727-fb22c43d9f10</div>
<div>Set id: 9ce9adc8-6fa2-4444-8386-14cd576ac63d</div>
<div>Version: 1</div>
<div>Effective Time: 20090801</div>
</div>
</div> <div class="DistributorName">Physicians Total Care, Inc.</div></p>
</body></html>
